Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria

Next Previous
Trial Profile

An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ravulizumab (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Alexion AstraZeneca Rare Disease

    • Most Recent Events

    • 17 Jun 2022 Results of pooled analysis assessing long-term complement inhibition and survival outcomes of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria from phase 1b, 2 and 3 trials (103 [NCT02598583], 201 [NCT02605993], 301 [NCT02946463] and 302 [NCT03056040]) with up to 4 years of open-label extension, presented at the 27th Congress of the European Haematology Association.
    • 22 Apr 2022 Status changed from active, no longer recruiting to completed.
    • 21 May 2019 Planned End Date changed from 1 Aug 2018 to 1 Jun 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top